---
document_datetime: 2025-12-29 09:01:19
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0.html
document_name: mylotarg-0.html
version: success
processing_time: 0.0629354
conversion_datetime: 2025-12-30 03:19:25.455187
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Mylotarg

[RSS](/en/individual-human-medicine.xml/65794)

##### Refused

This medicine has been refused authorisation

gemtuzumab ozogamicin Medicine Human Refused

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [Application details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Mylotarg](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 20 September 2007, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Mylotarg 5 mg powder for solution for infusion, intended for the treatment of acute myeloid leukaemia. The company that applied for authorisation is Wyeth Europa Ltd. The applicant requested a re-examination of the opin ion. After having considered the grounds for this request, the CHMP re-examined the initial opinion , and confirmed the refusal of the marketing authorisation on 24 January 2008.

Questions and answers on the recommendation for the refusal of the marketing authorization for Mylotarg

English (EN) (35.14 KB - PDF)

**First published:** 24/01/2008

**Last updated:** 24/01/2008

[View](/en/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_en.pdf)

[Other languages (21)](#file-language-dropdown-92)

български (BG) (181.19 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/bg/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_bg.pdf)

español (ES) (34.57 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/es/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_es.pdf)

čeština (CS) (139.98 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/cs/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_cs.pdf)

dansk (DA) (34.62 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/da/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_da.pdf)

Deutsch (DE) (34.76 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/de/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_de.pdf)

eesti keel (ET) (33.7 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/et/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_et.pdf)

ελληνικά (EL) (180.22 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/el/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_el.pdf)

français (FR) (34.13 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/fr/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_fr.pdf)

italiano (IT) (34.23 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/it/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_it.pdf)

latviešu valoda (LV) (146.46 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/lv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_lv.pdf)

lietuvių kalba (LT) (117.91 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/lt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_lt.pdf)

magyar (HU) (115.28 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/hu/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_hu.pdf)

Malti (MT) (157.27 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/mt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_mt.pdf)

Nederlands (NL) (34.13 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/nl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_nl.pdf)

polski (PL) (123.87 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/pl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_pl.pdf)

português (PT) (32.9 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/pt/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_pt.pdf)

română (RO) (149.11 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/ro/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_ro.pdf)

slovenčina (SK) (121.71 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/sk/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_sk.pdf)

slovenščina (SL) (113.35 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/sl/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_sl.pdf)

Suomi (FI) (33.39 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/fi/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_fi.pdf)

svenska (SV) (34.15 KB - PDF)

**First published:**

24/01/2008

**Last updated:**

24/01/2008

[View](/sv/documents/smop-initial/questions-and-answers-recommendation-refusal-marketing-authorization-mylotarg_sv.pdf)

## Product details

Name of medicine Mylotarg Active substance gemtuzumab ozogamicin International non-proprietary name (INN) or common name gemtuzumab ozogamicin Therapeutic area (MeSH) Leukemia, Myeloid, Acute Anatomical therapeutic chemical (ATC) code L01XC05

### Pharmacotherapeutic group

Antineoplastic agents

## Application details

EMA product number EMEA/H/C/000705

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation applicant Wyeth Europa Ltd Opinion adopted 24/01/2008 Refusal of marketing authorisation 14/04/2008

## Assessment history

Mylotarg : EPAR - Refusal public assessment report

English (EN) (371.18 KB - PDF)

**First published:** 17/04/2008

**Last updated:** 17/04/2008

[View](/en/documents/assessment-report/mylotarg-epar-refusal-public-assessment-report_en.pdf)

#### More information on Mylotarg

- [EU/3/00/005 - orphan designation for treatment of acute myeloid leukaemia](/en/medicines/human/orphan-designations/eu-3-00-005)

**This page was last updated on** 24/01/2008

## Share this page

[Back to top](#main-content)